循环肿瘤细胞分离富集技术及其在肺癌中的临床应用进展

doi:10.3969/j.issn.1004-616x.2024.02.014

摘要/Abstract

摘要： 癌症是一个主要的公共卫生问题，在中国，肺癌在所有癌症中发病率与死亡率均居于首位。由于肺癌患者随着病程进展生存率降低，因此肺癌的筛查与早期诊断显得尤为重要。液体活检具有微创、便捷、可重复的优点，是肺癌早期诊断与筛查的有力手段，其中循环肿瘤细胞(CTCs)是重要的液体活检标志物。CTCs作为转移病灶的“种子”，在癌症的早期诊断、转移监测、预后评价以及患者的个体比治疗中具有重要作用。但 CTCs在血液中含量稀少，需要将其从血细胞中分离富集出来，再进行分析。因此，本文对目前循环肿瘤细胞的分离富集技术，以及循环肿瘤细胞在肺癌中的临床应用进行综述。

关键词: 循环肿瘤细胞, 分离富集技术, 肺癌, 临床应用, 肿瘤诊断

中图分类号:

R734.2

霍迟未, 合思甜, 丁丽华, 吴拥军. 循环肿瘤细胞分离富集技术及其在肺癌中的临床应用进展[J]. 癌变·畸变·突变, 2024, 36(2): 159-163.

参考文献

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] ZENG H M, CHEN W Q, ZHENG R S, et al. Changing cancer survival in China during 2003-15:a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5):e555-e567.
[3] SHEN S Y, SINGHANIA R, FEHRINGER G, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes[J]. Nature, 2018, 563(7732):579-583.
[4] GUIBERT N, PRADINES A, FAVRE G, et al. Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages[J]. Eur Respir Rev, 2020, 29(155):190052.
[5] ECONOMOPOULOU P, GEORGOULIAS V, KOTSAKIS A. Classifying circulating tumor cells to monitor cancer progression[J]. Expert Rev Mol Diagn, 2017, 17(2):153-165.
[6] HOFMAN P, POPPER H H. Pathologists and liquid biopsies:to be or not to be?[J]. Virchows Arch, 2016, 469(6):601-609.
[7] SHEN Z Y, WU A G, CHEN X Y. Current detection technologies for circulating tumor cells[J]. Chem Soc Rev, 2017, 46(8):2038-2056.
[8] HAN Y Y, GU Y, ZHANG A C, et al. Review:imaging technologies for flow cytometry[J]. Lab Chip, 2016, 16(24):4639-4647.
[9] COUMANS F A, VAN DALUM G, BECK M, et al. Filter characteristics influencing circulating tumor cell enrichment from whole blood[J]. PLoS One, 2013, 8(4):e61770.
[10] VONA G, SABILE A, LOUHA M, et al. Isolation by size of epithelial tumor cells:a new method for the immunomorphological and molecular characterization of circulatingtumor cells[J]. Am J Pathol, 2000, 156(1):57-63.
[11] HAROUAKA R A, ZHOU M D, YEH Y T, et al. Flexible micro spring array device for high-throughput enrichment of viable circulating tumor cells[J]. Clin Chem, 2014, 60(2):323-333.
[12] 王建,邵荣金,龚伟达.循环肿瘤细胞研究进展[J].中国肿瘤外科杂志, 2019, 11(2):141-145.
[13] ROSSI T, GALLERANI G, ANGELI D, et al. Single-cell NGS-based analysis of copy number alterations reveals new insights in circulating tumor cells persistence in early-stage breast cancer[J]. Cancers, 2020, 12(9):2490.
[14] PAPADAKI M A, SOTIRIOU A I, VASILOPOULOU C, et al. Optimization of the enrichment of circulating tumor cells for downstream phenotypic analysis in patients with non-small cell lung cancer treated with anti-PD-1 immunotherapy[J]. Cancers, 2020, 12(6):1556.
[15] ROSENBERG R, GERTLER R, FRIEDERICHS J, et al. Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood[J]. Cytometry, 2002, 49(4):150-158.
[16] BALASUBRAMANIAN P, KINDERS R J, KUMMAR S, et al. Antibody-independent capture of circulating tumor cells of nonepithelial origin with the ApoStream^® system[J]. PLoS One, 2017, 12(4):e0175414.
[17] GAO T, LI W J, MA J L, et al. Selection of DNA aptamer recognizing CD44 for high-efficiency capture of circulating tumor cells[J]. Talanta, 2023, 262:124728.
[18] CAO H X, LIU P F, WANG L, et al. Nonenzymatic chemiluminescence detection of circulating tumor cells in blood based on Au@luminol nanoparticles, hybridization chain reaction and magnetic isolation[J]. Sens Actuat B Chem, 2020, 318:128287.
[19] QIAN H Z, ZHANG Y, XU J, et al. Progress and application of circulating tumor cells in non-small cell lung cancer[J]. Mol Ther Oncolytics, 2021, 22:72-84.
[20] TANAKA F, YONEDA K, KONDO N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer[J]. Clin Cancer Res, 2009, 15(22):6980-6986.
[21] CHEN X X, ZHOU F, LI X F, et al. Folate receptor-positive circulating tumor cell detected by LT-PCR-based method as a diagnostic biomarker for non-small-cell lung cancer[J]. J Thorac Oncol, 2015, 10(8):1163-1171.
[22] MANJUNATH Y, UPPARAHALLI S V, SUVILESH K N, et al. Circulating tumor cell clusters are a potential biomarker for detection of non-small cell lung cancer[J]. Lung Cancer, 2019, 134:147-150.
[23] ILIE M, HOFMAN V, LONG-MIRA E, et al. "Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease[J]. PLoS One, 2014, 9(10):e111597.
[24] FIORELLI A, ACCARDO M, CARELLI E, et al. Circulating tumor cells in diagnosing lung cancer:clinical and morphologic analysis[J]. Ann Thorac Surg, 2015, 99(6):1899-1905.
[25] WANG L, WU C Y, QIAO L H, et al. Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in lung cancer[J]. J Cancer, 2017, 8(1):104-110.
[26] JIN F K, ZHU L, SHAO J B, et al. Circulating tumour cells in patients with lung cancer universally indicate poor prognosis[J]. Eur Respir Rev, 2022, 31(166):220151.
[27] WANG J W, WANG K, XU J J, et al. Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients:a meta-analysis[J]. PLoS One, 2013, 8(11):e78070.
[28] YU Y, CHEN Z L, DONG J S, et al. Folate receptor-positive circulating tumor cells as a novel diagnostic biomarker in non-small cell lung cancer[J]. Transl Oncol, 2013, 6(6):697-702.
[29] KREBS M G, SLOANE R, PRIEST L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer[J]. J Clin Oncol, 2011, 29(12):1556-1563.
[30] NAITO T, TANAKA F, ONO A, et al. Prognostic impact of circulating tumor cells in patients with small cell lung cancer[J]. J Thorac Oncol, 2012, 7(3):512-519.
[31] TONG B, XU Y, ZHAO J, et al. Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer[J]. Thorac Cancer, 2018, 9(5):640-645.
[32] CHINNIAH C, AGUARIN L, CHENG P, et al. Early detection of recurrence in patients with locally advanced non-small-cell lung cancer via circulating tumor cell analysis[J]. Clin Lung Cancer, 2019, 20(5):384-390.e2.
[33] HOU J M, GREYSTOKE A, LANCASHIRE L, et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy[J]. Am J Pathol, 2009, 175(2):808-816.
[34] MURRAY N, TURRISI A T 3rd. A review of first-line treatment for small-cell lung cancer[J]. J Thorac Oncol, 2006, 1(3):270-278.
[35] LIU D G, XUE L, LI J, et al. Epithelial-mesenchymal transition and GALC expression of circulating tumor cells indicate metastasis and poor prognosis in non-small cell lung cancer[J]. Cancer Biomark, 2018, 22(3):417-426.
[36] KULASINGHE A, KAPELERIS J, KIMBERLEY R, et al. The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer[J]. Cancer Med, 2018, 7(12):5910-5919.
[37] TARTARONE A, ROSSI E, LEROSE R, et al. Possible applications of circulating tumor cells in patients with non small cell lung cancer[J]. Lung Cancer, 2017, 107:59-64.
[38] LIU Y F, XING Z, ZHAN P, et al. Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?:a meta-analysis[J]. Medicine, 2016, 95(47):e5115.
[39] ZHANG X, YANG D Y, JIANG Y, et al. Comparison of radiation pneumonitis in lung cancer patients treated with HT versus IMRT and circulating lymphocyte subsets as predicting risk factors[J]. J Inflamm Res, 2021, 14:4205-4215.
[40] ILIE M, LONG E, BUTORI C, et al. ALK-gene rearrangement:a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma[J]. Ann Oncol, 2012, 23(11):2907-2913.
[41] PAILLER E, FAUGEROUX V, OULHEN M, et al. Acquired resistance mutations to ALK inhibitors identified by single circulating tumor cell sequencing in ALK-rearranged non-small-cell lung cancer[J]. Clin Cancer Res, 2019, 25(22):6671-6682.
[42] LAZZARI C, KARACHALIOU N, BULOTTA A, et al. Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer:is this the beginning of the end for cancer?[J]. Ther Adv Med Oncol, 2018, 10:1758835918762094.
[43] 徐静,高雯.循环肿瘤细胞在肺癌中的研究应用与未来展望[J].医学研究生学报, 2022, 35(9):897-902.
[44] YUE C Y, JIANG Y B, LI P, et al. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy[J]. Oncoimmunology, 2018, 7(7):e1438111.
[45] ALAMA A, COCO S, GENOVA C, et al. Prognostic relevance of circulating tumor cells and circulating cell-free DNA association in metastatic non-small cell lung cancer treated with nivolumab[J]. J Clin Med, 2019, 8(7):1011.
[46] LABIB M, KELLEY S O. Circulating tumor cell profiling for precision oncology[J]. Mol Oncol, 2021, 15(6):1622-1646.
[47] PANTEL K, ALIX-PANABIÈRES C. Liquid biopsy and minimal residual disease-latest advances and implications for cure[J]. Nat Rev Clin Oncol, 2019, 16:409-424.
[48] WU C P, WU P, ZHAO H F, et al. Clinical applications of and challenges in single-cell analysis of circulating tumor cells[J]. DNA Cell Biol, 2018, 37(2):78-89.
[49] DAI Z, GU X Y, XIANG S Y, et al. Research and application of single-cell sequencing in tumor heterogeneity and drug resistance of circulating tumor cells[J]. Biomark Res, 2020, 8(1):60.